Literature DB >> 28446809

Blood pressure management in patients with type 2 diabetes mellitus.

Hisashi Kai1.   

Abstract

Hypertension aggravates macrovascular and microvascular diseases and mortality in patients with type 2 diabetes mellitus (T2DM). The current Japanese Society of Hypertension Guidelines of the Management of Hypertension (JSH 2014) recommends that antihypertensive medication should be initiated concomitantly with lifestyle modification when blood pressure (BP) is ⩾130/80 mm Hg and that target levels of office and home BP should be <130/80 mm Hg and <125/75 mm Hg, respectively, in T2DM patients. Considering more favorable metabolic profiles and renoprotective effects than other classes of antihypertensive agents, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are recommended as the first-line therapy for patients with hypertension and T2DM in JSH 2014. However, the target BP and the first-line therapy remain controversial because of the paucity of high-quality evidence with consistency. It is suggested that BP management should be tailored for each patient with T2DM, based on tolerability and considerations of comorbidity.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28446809     DOI: 10.1038/hr.2017.55

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  76 in total

1.  Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).

Authors:  Josep Redon; Giuseppe Mancia; Peter Sleight; Helmut Schumacher; Peggy Gao; Janice Pogue; Robert Fagard; Paolo Verdecchia; Michael Weber; Michael Böhm; Bryan Williams; Khalid Yusoff; Koon Teo; Salim Yusuf
Journal:  J Am Coll Cardiol       Date:  2012-01-03       Impact factor: 24.094

2.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

3.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

4.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

5.  Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.

Authors:  Giancarlo Viberti; Nigel M Wheeldon
Journal:  Circulation       Date:  2002-08-06       Impact factor: 29.690

Review 6.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

7.  Prevalence of hypertension and controlled hypertension - United States, 2007-2010.

Authors:  Cathleen D Gillespie; Kimberly A Hurvitz
Journal:  MMWR Suppl       Date:  2013-11-22

Review 8.  Diabetic patients and beta-blockers after acute myocardial infarction.

Authors:  J Kjekshus; E Gilpin; G Cali; A R Blackey; H Henning; J Ross
Journal:  Eur Heart J       Date:  1990-01       Impact factor: 29.983

Review 9.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors:  Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321

Review 10.  SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

Authors:  Naveed Sattar; James McLaren; Søren L Kristensen; David Preiss; John J McMurray
Journal:  Diabetologia       Date:  2016-04-25       Impact factor: 10.122

View more
  4 in total

1.  Canagliflozin improves obesity and insulin resistance in a diabetic patient with Cushings disease undergoing postoperative steroid therapy: A case report.

Authors:  Kota Nishihama; Noriko Furuta; Kanako Maki; Yuko Okano; Rei Hashimoto; Yasuhiro Hotta; Mei Uemura; Taro Yasuma; Toshinari Suzuki; Corina N D'Alessandro-Gabazza; Yutaka Yano; Esteban C Gabazza
Journal:  Biomed Rep       Date:  2018-10-01

2.  Diabetic nephropathy ameliorated in patients with normal home blood pressure compared to those with isolated high home systolic blood pressure: A 5-year prospective cohort study among patients with type 2 diabetes mellitus.

Authors:  Nobuko Kitagawa; Emi Ushigome; Noriyuki Kitagawa; Hidetaka Ushigome; Isao Yokota; Naoko Nakanishi; Masahide Hamaguchi; Mai Asano; Masahiro Yamazaki; Michiaki Fukui
Journal:  Diab Vasc Dis Res       Date:  2022 May-Jun       Impact factor: 3.541

3.  Impact of Isolated High Home Systolic Blood Pressure and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus: A 5-Year Prospective Cohort Study.

Authors:  Nobuko Kitagawa; Noriyuki Kitagawa; Emi Ushigome; Hidetaka Ushigome; Isao Yokota; Naoko Nakanishi; Masahide Hamaguchi; Mai Asano; Masahiro Yamazaki; Michiaki Fukui
Journal:  J Clin Med       Date:  2021-04-29       Impact factor: 4.241

4.  Nationwide Survey on Actual Interventions for Type 2 Diabetes by Japanese Practitioners (NSAID Study-1): Glycemic, Weight, and Blood Pressure Management.

Authors:  Keiko Arai; Tetsuo Nishikawa; Shohei Yuasa; Shin-Ichiro Shirabe; Yoko Matsuzawa; Shigeyuki Ohtsu; Koich Hirao; Hisao Mori
Journal:  Diabetes Ther       Date:  2020-05-22       Impact factor: 2.945

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.